Add to ORKGTreatment of myelodysplastic syndromes (MDS) has improved in recent years with better results of allogeneic stem cell therapy (SCT), the advent of new therapeutic options such as hypomethylating agents and lenalidomide, the introduction of iron chelation therapy and the implication of erythropoietic stimulating agents in the treatment of anemia. In this review, we summarize the different diagnostic and prognostic criteria and outline the different treatment options we have in 2011
Myelodysplastic syndromes (MDS) comprise a heterogeneous group of malignant hematopoietic stem cell ...
Azacytidine: first therapeutic opportunity for myelodysplastic syndromes Myelodysplastic syndromes (...
Abstract Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disord...
Myelodysplastic syndromes (MDS) are a poorly understood group of disorders caused by one or more gen...
In the last decade, significant advances have been made in the treatment of patients with Myelodyspl...
In the last decade, significant advances have been made in the treatment of patients with Myelodyspl...
Diagnosis and treatment of myelodysplastic syndromes The myelodysplastic syndromes (MDS) are hetero...
Treatment of myelodysplastic syndromes (MDS) has evolved to encompass a broad spectrum of therapies ...
As opposed to the treatment landscape for myelodysplastic syndromes (MDS) two decades ago, poten-tia...
Introduction: An accurate diagnostic and prognostic evaluation of patients with myelodysplastic synd...
The authors conducted a systematic review of the medical literature published in the past 15 years o...
Background and Objectives. Novel therapeutic agents and strategies have been introduced into the man...
Myelodysplastic syndromes (MDS) represent a heterogeneous group of haematological disorders characte...
International audienceMyelodysplastic syndromes (MDS) are a group of common bone marrow disorders ch...
Myelodysplastic syndromes (MDS) represent a heterogeneous group of haematological disorders characte...
Myelodysplastic syndromes (MDS) comprise a heterogeneous group of malignant hematopoietic stem cell ...
Azacytidine: first therapeutic opportunity for myelodysplastic syndromes Myelodysplastic syndromes (...
Abstract Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disord...
Myelodysplastic syndromes (MDS) are a poorly understood group of disorders caused by one or more gen...
In the last decade, significant advances have been made in the treatment of patients with Myelodyspl...
In the last decade, significant advances have been made in the treatment of patients with Myelodyspl...
Diagnosis and treatment of myelodysplastic syndromes The myelodysplastic syndromes (MDS) are hetero...
Treatment of myelodysplastic syndromes (MDS) has evolved to encompass a broad spectrum of therapies ...
As opposed to the treatment landscape for myelodysplastic syndromes (MDS) two decades ago, poten-tia...
Introduction: An accurate diagnostic and prognostic evaluation of patients with myelodysplastic synd...
The authors conducted a systematic review of the medical literature published in the past 15 years o...
Background and Objectives. Novel therapeutic agents and strategies have been introduced into the man...
Myelodysplastic syndromes (MDS) represent a heterogeneous group of haematological disorders characte...
International audienceMyelodysplastic syndromes (MDS) are a group of common bone marrow disorders ch...
Myelodysplastic syndromes (MDS) represent a heterogeneous group of haematological disorders characte...
Myelodysplastic syndromes (MDS) comprise a heterogeneous group of malignant hematopoietic stem cell ...
Azacytidine: first therapeutic opportunity for myelodysplastic syndromes Myelodysplastic syndromes (...
Abstract Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disord...